Thursday 22 October 2020

Takeda partners with global plasma firms in big Covid fight

DUBAI, September 15, 2020

Takeda, one of the world's leading global biopharmaceutical companies, has joined forces with some of the world's leading plasma companies to focus on developing a hyperimmune globulin in the worldwide fight against Covid-19 pandemic.
Spearheading the Covid fight from its brand-new Dubai address and also the headquarters for India, CIS, the Middle East, including Turkey & Africa (ICMEA), Takeda said the CoVIg-19 Plasma Alliance is an unparalleled partnership.
Tracing Takeda's roots in Japan back to 1781, the companys new office at One Central at Dubai World Trade Centre carefully curates' Japanese elements. The design details are subtly reflected in the corporate philosophy in its four values: Integrity, Fairness, Honesty, and Perseverance. 
Takeda's ICMEA business is part of its Growth & Emerging Business Unit (GEM), one of four Regional Business Units that make-up its worldwide commercial operations: The US, Japan, Europe & Canada (Eucan) and GEM.
"Advances in research and development have been pushing the boundaries of science over the years, and we have been playing our part in helping bring transformative, life-changing therapies to patients across disease areas," remarked Takeda Senior VP and Area Head, Mahender Nayak. 
"Through groundbreaking initiatives such as the Mohammed bin Rashid Medical Research Institute, the community will surely benefit from research studies and scientific insights that are reflective and more specific to the regional population profile," stated Nayak. 
Its added focus on genetic studies will help the Institute resolve critical unmet medical needs while supporting the endeavors of organizations such as Takeda by building on combined strengths across all stages of discovery, development and commercialization, alongside its own global team of researchers and scientists, he added.
On the new office, Nayak said Takeda's new area offices based at One Central at Dubai World Trade Centre houses the hub team for the ICMEA Area. 
"Following Takeda's recent 239th birthday as a company, we felt it suitable to introduce the new state-of-the-art facility, merging the worlds of science and Japanese tradition to provide a refreshed environment for our team members," he noted.
Highlighting the key LEED initiatives at its new office, Nayak said: "One Central at DWTC itself is recognized for its green credentials, achieving Gold level certification by LEED standards, with Takeda's offices receiving Silver level certification. Takeda's values of Integrity, Honesty, Fairness, and Perseverance guide us in our obligation to protect the environment and our patients and motivate us to act urgently on climate change."
Welcoming the Japanese group, Helal Saeed Almarri, Director General, Dubai World Trade Centre Authority (DWTCA) and Dubai Department of Tourism and Commerce Marketing (DTCM), said: "As one of the world's leading global biopharmaceutical companies, relocating its new area office for ICMEA to One Central to cover a wider geographic area emphasizes both the strategic importance of the development and supports Dubai's attractiveness to international corporations as a global dynamic business destination of choice."
"DWTCA's One Central development continues to deliver a distinctive proposition that highlights Dubai's global status as a progressive, technologically advanced hub for international business," he added.-TradeArabia News Service


More Health & Environment Stories

calendarCalendar of Events